Molecular Profiling: Getting to Know Your Tumor
Dr. Johanna Bendell explains the value of molecular profiling. It can indicate which type of chemotherapy will be more successful on your tumor.
Novel Drug Combination Plus Radiation for Locally Advanced Pancreatic Cancer
A clinical trial combines immunotherapy, common treatments, an antiretroviral drug, and SBRT for locally advanced pancreatic cancer.
Tumor Genetics Research Brings Some Answers for Families at High Risk
Professor Gloria Peterson of the Mayo Clinic is working on tumor genetics to help make early detection of pancreatic cancer a reality.
Investigating a Drug Used for Other Cancers
Researchers are adding the drug decitabine to gemcitabine, in a clinical trial for patients with advanced cancer that is not responding to treatment.
New Drug for BRCA Carriers with Advanced Cancer
A phase I clinical trial is testing the effectiveness of a platinum-based drug for BRCA carriers with pancreatic, breast, and other cancers.
Pre-surgical Treatment for Pancreatic Cancer that is Removable
A clinical trial looks at immunotherapy plus vitamin D plus standard chemotherapy before surgery to remove pancreatic cancer.
Most Cancer Mutations Are Random DNA Mistakes
In a large study, Dr. Bert Vogelstein of Johns Hopkins found that a majority of cancers, including pancreatic cancer, are caused by random mutations of DNA.
An Immunotherapy Game Changer
Immunotherapy with Keytruda (pembrolizumab) is approved for use in cancer patients with certain genetic defects in their tumors.
Testing the Safety of a New Chemotherapy and Radiation Combination
A clinical trial tests the effectiveness of adding PEGPH20 to standard chemotherapy and radiation in patients with locally advanced pancreatic cancer.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.